Clinical & Experimental Neuroscience Group
The Clinical & Experimental Neuroscience group is headed by Prof. Dr. Rejko Krüger and is majorly funded by a Programme Excellence Award for Research in Luxembourg (PEARL) by the National Research Fund (FNR). Prof. Krüger combines fundamental research in the area of Parkinson’s disease with clinical practice as neurologist at the Centre Hospitalier du Luxembourg.
The Clinical & Experimental Neuroscience group at the LCSB. From left to right: Bruno Santos, François Massart, Dr. Peter Barbuti, Gérald Cruciani, Zoé Hanss, Marie Estelle Schmidt, Grazia Ianello, Clara Berenguer, Iga Ciesielska, Simone Larsen, Dr. Jaclyn Nicole Le Grand, Jill Bohler, Dr. Mary Faltz, Dr. Ibrahim Boussaad, Géraldine Hipp, Dajana Grossman, Prof. Dr. Rejko Krüger
About the Clinical & Experimental Neuroscience Group
One major focus of the research group is the elucidation of molecular signaling pathways leading to neurodegeneration in Parkinson's disease. Using mutation screenings in a large sample of Parkinson patients, the group has identified novel mutations in genes that are responsible for familial PD and deciphered genetic variants in candidate genes that are associated with sporadic PD. The group intensively studies the functional consequences of identified mutations, investigating molecular signalling cascades in the pathogenesis of PD. In this context, we are interested in the identification of novel interacting proteins, characterization of proteasomal function, analyses of mitochondrial function and dynamics, and the effects of cell viability in cellular and transgenic animal models of the disease. These studies aim at the development of novel neuroprotective therapeutic strategies in the treatment of PD as the most common neurodegenerative movement disorder.
The Clinical and Experimental Neuroscience Group is supported by: